In this regard, Melas and colleagues in 2013 investigated phosphoproteome changes in 3 HCC cell lines upon treatment with eight drugs including lapatinib, gefitinib, erlotinib (EGFR inhibitors), sorafenib (inhibitor of VEGFR, PDGFR and of Raf kinases C-Raf and B-Raf), vandetanib (VEGFR and EGFR antagonist), sunitinib (PDGFR and VEGFR kinase inhibitor), dasatinib (multi-BCR/ABL and Src family kinase inhibitor), and bortezomib (proteasome inhibitor) for unresectable HCC, in order to identify the phosphoproteomic signatures that are predictive of drug efficacy. This evidence concerns the gene PDGFRB and hepatocellular carcinoma.